tbuckley/cabot-search huggingface dataset:
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
Authors: Ye Li, Rafet Basar, Guohui Wang, Enli Liu, Judy S. Moyes, Li Li, Lucila N. Kerbauy, Nadima Uprety, Mohsen Fathi, Ali Rezvan, Pinaki P. Banerjee, Luis Muniz-Feliciano, Tamara J. Laskowski, Emily Ensley, May Daher, Mayra Shanley, Mayela Mendt, Sunil Acharya, Bin Liu, Alexander Biederstädt, Hind Rafei, Xingliang Guo, Luciana Melo Garcia, Paul Lin, Sonny Ang, David Marin, Ken Chen, Laura Bover, Richard E. Champlin, Navin Varadarajan, Elizabeth J. Shpall, Katayoun Rezvani
Journal: Nature Medicine (2022)
The Thyroid Gland and &lt;italic&gt;N-2&lt;/italic&gt;-Fluorenyldiacetamide Carcinogenesis and Cirrhosis of the Liver in Wistar Male Rats&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1965)

Journal Article The Thyroid Gland and N-2-Fluorenyldiacetamide Carcinogenesis and Cirrhosis of the Liver in Wistar Male Rats Get access Melvin D. Reuber Melvin D. Reuber Laboratory of Pathology, National Cancer Institute,4Bethesda, Maryland, and Department of Pathology, Harvard Medical School, and Beth Israel Hospital, Boston, Massachusetts Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 35, Issue 6, December 1965, Pages 959–966, https://doi.org/10.1093/jnci/35.6.959 Published: 01 December 1965 Article history Received: 24 February 1965 Published: 01 December 1965
Carcinogenic Effects of Polycyclic Hydrocarbon Carcinogen Administration to Mice During Pregnancy on the Progeny&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1971)

Intraperitoneal injections of either benzo[a]pyrene (BP) or 7,12-dimethylbenzlaJanthracene (DMBA) into mice during the last half of pregnancy resulted in an increased incidence of pulmonary adenomas and skin papillomas in progeny that were delivered surgically and nursed on foster mothers. The progeny of DMBA-treated mothers also developed ovarian tumors that were not observed in progeny of controls or BP-treated mothers.
LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
Authors: M.F. Mosele, A. Lusque, V.C. Dieras, E. Deluche, A. Ducoulombier, B. Pistilli, T. Bachelot, F. Viret, C. Levy, Y.C. Pradat, D.T.N. Tran, N. Droin, M. Kobayashi, T. Kakewaga, M. Deloger, B. Job, M. Jimenez, M. Lacroix-Triki, F. André
Journal: Annals of Oncology (2022)
LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial
Authors: M. Özgüroğlu, S. Kilickap, A. Sezer, M. Gumus, I. Bondarenko, M. Gogishvili, M. Nechaeva, M. Schenker, I. Cicin, G.F. Ho, Y. Kulyaba, M. Dvorkin, K. Zyuhal, R.I. Scheusan, S. Li, J-F. Pouliot, F. Seebach, I. Lowy, G. Gullo, P. Rietschel
Journal: Annals of Oncology (2022)
LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
Authors: E.B. Garon, S. Lu, Y. Goto, P.R. De Marchi, L. Paz-Ares, D.R. Spigel, M. Thomas, J.C-H. Yang, A. Ardizzoni, F. Barlesi, S. Khanna, C. Bossen, M. Carbini, A. Yovine, B.C. Cho
Journal: Annals of Oncology (2022)
LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
Authors: A. Bex, R. Uzzo, J.A. Karam, V.A. Master, F. Donskov, C. Suárez, L. Albiges, B.I. Rini, Y. Tomita, A. Kann, G. Procopio, F. Massari, M. Zibelman, I. Antonyan, M. Huseni, D. Basu, B. Ci, W. Leung, O. Khan, S.K. Pal
Journal: Annals of Oncology (2022)
LBA63 PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
Authors: R. Aggarwal, G. Heller, D. Hillman, H. Xiao, J. Picus, J. Wang, M.E. Taplin, T. Dorff, L.J. Appleman, D. Weckstein, A. Patnaik, A.H. Bryce, D. Shevrin, J. Mohler, D. Anderson, A. Rao, S.T. Tagawa, A. Tan, S. Eggener, M.J. Morris
Journal: Annals of Oncology (2022)
LBA60 Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study
Authors: C. de la Fouchardiere, D. Malka, S. Chabaud, J. Raimbourg, D. Botsen, S. Launay, L. Evesque, A. Vienot, H. Perrier, M. Jary, Y. Rinaldi, C. Coutzac Bergouignan, J-B. Bachet, C. Neuzillet, N. Williet, R. Desgrippes, G. Brard, N. Lachaux, O. Bouche, F. Ghiringhelli
Journal: Annals of Oncology (2022)
LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
Authors: T.B. Powles, S. Sridhar, J. Bellmunt, C. Sternberg, P. Grivas, E. Hunter, M. Dezfouli, M. Salter, R. Powell, A. Dring, J. Green, A. Akoulitchev, R. Amezquita, K. Ching, J. Pu, S. Deng, A. di Pietro, C.B. Davis
Journal: Annals of Oncology (2022)
LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
Authors: J.E. Rosenberg, M. Milowsky, C. Ramamurthy, N. Mar, R.R. McKay, T. Friedlander, C. Ferrario, S. Bracarda, S. George, H. Moon, D. Geynisman, D.P. Petrylak, D. Borchiellini, E.F. Burgess, J.P. Maroto Rey, A-S. Carret, Y. Yu, M.V. Guseva, B. Homet Moreno, P.H. O'Donnell
Journal: Annals of Oncology (2022)
LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)
Authors: B. Kasper, R. Ratan, T. Alcindor, P. Schoeffski, W.T.A. van der Graaf, B.A. Wilky, R.F. Riedel, A. Lim, L.M. Smith, S. Moody, S. Attia, S.P. Chawla, G. D'Amato, N. Federman, P. Van Tine, B.A. Van Tine, B. Vincenzi, S. Kummar, M.M. Gounder
Journal: Annals of Oncology (2022)
LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816
Authors: J.S. Deutsch, A. Cimino-Mathews, E.D. Thompson, D. Wang, R.A. Anders, E. Gabrielson, P. Illei, J. Jedrych, L. Danilova, J. Spicer, M. Provencio Pulla, P.M. Forde, D. Pandya, M.P. Tran, J. Fiore, V. Devas, T.R. Cottrell, A.S. Baras, J.M. Taube
Journal: Annals of Oncology (2022)
LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
Authors: S.M. Lee, C. Schulz, K. Prabhash, B. Han, A. Szczesna, D.L. Cortinovis, A. Rittmeyer, D. Vicente Baz, R. Califano, L. Tuan Anh, G. Liu, F. Cappuzzo, J.G. Reyes Contreras, M. Reck, Y. Hu, S. Morris, E.K. Hoeglander, M. Connors, H.K.M. Vollan, S. Peters
Journal: Annals of Oncology (2022)
LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
Authors: M.L. Johnson, A.J. de Langen, D.M. Waterhouse, J. Mazieres, A-M.C. Dingemans, G. Mountzios, M. Pless, J. Wolf, M. Schuler, H. Lena, F. Skoulidis, I. Okamoto, S-W. Kim, H. Linardou, S. Novello, Y. Chen, B. Solomon, C. Obiozor, Y. Wang, L. Paz-Ares
Journal: Annals of Oncology (2022)
LBA59 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
Authors: M. Johnson, B.C. Cho, A. Luft, J. Alatorre-Alexander, S.L. Geater, K. Laktionov, S-W. Kim, G. Ursol, M. Hussein, F.L. Lim, C.T. Yang, L.H. Araujo, H. Saito, N. Reinmuth, Z. Lai, H. Mann, X. Shi, S. Peters, E. Garon, T.S.K. Mok
Journal: Annals of Oncology (2022)
LBA57 Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study
Authors: B. Han, T. Chu, Z. Yu, J. Wang, Y. Zhao, X. Mu, X. Yu, X. Shi, Q. Shi, M. Guan, C. Ding, N. Geng
Journal: Annals of Oncology (2022)
LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial
Authors: M-J. Ahn, S-W. Kim, E. Carcereny Costa, L.M. Rodríguez, J. Oliveira, M.A. Insa Molla, M. Majem, L. Costa, W-C. Su, K.H. Lee, J.C-H. Yang, D.R. Spigel, E.K. Cho, M. D'Arcangelo, M.R. Garcia Campelo, A. Delmonte, P. Mitchell, I. Achour, D. Subramaniam, E. Felip
Journal: Annals of Oncology (2022)
LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
Authors: R.J. Motzer, P. Russo, V. Gruenwald, Y. Tomita, B. Zurawski, O.A. Parikh, S. Buti, P. Barthelemy, J.C.H. Goh, D. Ye, A. Lingua, J-B. Lattouf, B. Escudier, S. George, None B. Shuch, B. Simsek, J. Spiridigliozzi, A. Chudnovsky, A. Bex
Journal: Annals of Oncology (2022)
LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)
Authors: L. Wang, S. Qin, Y. Zhou, S. Zhang, X. Sun, Z. Chen, J. Cui, P. Zhao, K. Gu, Z. Li, J. Wang, X. Chen, J. Yao, L. Shen, J. Zhou, G. Wang, Y. Bai, Q. Wang, H. Wang
Journal: Annals of Oncology (2022)
LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study
Authors: T.A. Walter, A. Lievre, R. Coriat, D. Malka, F. El Hajbi, F. Di Fiore, O. Hentic Dhome, D. Smith, V. Hautefeuille, G. Roquin, M. Perrier, L. Dahan, None V. Granger, I. Sobhani, L. Mineur, P. Niccoli, E. Assenat, K. Le Malicot, C. Lepage, C. Lombard Bohas
Journal: Annals of Oncology (2022)
LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
Authors: K. Goto, K. Sang-We, T. Kubo, Y. Goto, M-J. Ahn, D. Planchard, D-W. Kim, J.C-H. Yang, T-Y. Yang, K.M.C. Pereira, K. Saxena, R. Shiga, Y. Cheng, M. Aregay, P.A. Jänne
Journal: Annals of Oncology (2022)
LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)
Authors: C.C. Parker, N. Clarke, A. Cook, C. Catton, W.R. Cross, H. Kynaston, J. Logue, P.M. Petersen, P. Neville, R. Persad, H. Payne, F. Saad, A. Stirling, W.R. Parulekar, M.K. Parmar, M.R. Sydes
Journal: Annals of Oncology (2022)
LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)
Authors: N. Tannir, M.N. Formiga, N. Agarwal, S.K. Pal, D. Cho, D.J. George, W. Hong, L. Tang, A. Qureshi, M.A. Tagliaferri, J. Zalevsky, K.D. Penkov
Journal: Annals of Oncology (2022)
LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data
Authors: S. Burdett, D. Fisher, C.C. Parker, M.R. Sydes, P. Pommier, P. Sargos, D.E. Spratt, A.U. Kishan, M. Brihoum, C. Catton, S. Chabaud, N. Clarke, A. Cook, I. Latorzeff, J. Tierney, C. Vale
Journal: Annals of Oncology (2022)
LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
Authors: J. Mazieres, T.M. Kim, B.K. Lim, M. Wislez, C. Dooms, G. Finocchiaro, H. Hayashi, C.K. Liam, J. Raskin, L.M. Tho, F. de Marinis, E. Nadal, E. Smit, X. Le, S. Brutlach, A.M. O'Brate Grupp, S. Adrian, B. Ellers-Lenz, N. Karachaliou, Y-L. Wu
Journal: Annals of Oncology (2022)
LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial
Authors: C.A. Rothermundt, R. Cathomas, K. Gysel, N. Fischer, R. Pereira Mestre, T. Hermanns, S.I. Rothschild, N. Mach, W. Mingrone, M. Ciriolo, B. Müller, A.A. Erdmann, C. Schär, C. Mamot, P. Bohanes, A.G. Omlin, S. Bastian, K. Ribi, S. Gillessen
Journal: Annals of Oncology (2022)
LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
Authors: G. Zalcman, Y. Oulkhouir, R. Cornelissen, L. Greillier, J.R. Rodriguez Cid, J. Mazieres, P. Briggs, A.K. Nowak, A. Tsao, N. Fujimoto, S. Peters, A.S. Mansfield, S. Popat, A. Nassar, J. Bushong, N. Hu, T. Spires, D. Balli, L. Eccles, P. Baas
Journal: Annals of Oncology (2022)
LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study
Authors: S. Lu, L. Wu, H. Jian, Y. Cheng, Q. Wang, J. Fang, Z. Wang, Y. Hu, L. Han, M. Sun, L. Miao, C. Ding, J. Cui, K. Wang, B. Li, X. Li, F. Ye, A. Liu, Y. Pan, S. Cang
Journal: Annals of Oncology (2022)
LBA53 ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
Authors: Z. Piotrowska, M-J. Ahn, Y.K. Pang, S.H. How, S-W. Kim, P.J. Voon, D.L. Cortinovis, J. De Castro Carpeno, M. Tiseo, D. Rodriguez Abreu, S.S. Ramalingam, J. Li, L. Servidio, S. Sadow, R.J. Hartmaier, B.C. Cho
Journal: Annals of Oncology (2022)
LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Authors: J. Remon Masip, B. Besse, S. Ponce Aix, A. Callejo, K. Al-Rabi, R. Bernabe Caro, L. Greillier, M. Majem Tarruella, N. Reguart Aransay, I. Monnet, S. Cousin, P. Garrido Lopez, G. Robinet, M.R. Garcia Campelo, A-C. Madroszyk Flandin, J. Mazieres, Y. Pretzenbacher, B. Fournier, A-M.C. Dingemans, R. Dziadziuszko
Journal: Annals of Oncology (2022)
LBA62 Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol
Authors: G. Attard, L. Murphy, N. Clarke, W. Cross, S. Gillessen, C. Amos, C. Brawley, R. Jones, C. Pezaro, Z. Malik, A. Montazeri, R. Millman, A. Cook, D. Gilbert, R. Langley, C. Parker, M. Sydes, L. Brown, M. Parmar, N. James
Journal: Annals of Oncology (2022)
LBA75 RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results
Authors: S.C. Schmid, K. Schiller, J. Lewerich, A.K. Seitz, A. Sauter, F. Koll, F. Beckert, P. Korn, P. Maisch, C. Rödel, M. Flentje, T. Wiegel, S. Combs, F. Zengerling, C. Bolenz, H. Kuebler, J. Gschwend, M. Retz
Journal: Annals of Oncology (2022)
Visualizing germination of microbiota endospores in the mammalian gut
Authors: Ningning Xu, Liyuan Lin, Yahui Du, Huibin Lin, Jia Song, Chaoyong Yang, Wei Wang
Journal: Gut Microbes (2022)

Transmission of bacterial endospores between the environment and people and the following germination in vivo play critical roles in both the deadly infections of some bacterial pathogens and the stabilization of the commensal microbiotas in humans. Our knowledge about the germination process of different bacteria in the mammalian gut, however, is still very limited due to the lack of suitable tools to visually monitor this process. We proposed a two-step labeling strategy that can image and quantify the endospores' germination in the recipient's intestines. Endospores collected from donor's gut microbiota were first labeled with fluorescein isothiocyanate and transplanted to mice via gavage. The recipient mice were then administered with Cyanine5-tagged D-amino acid to label all the viable bacteria, including the germinated endospores, in their intestines in situ. The germinated donor endospores could be distinguished by presenting two types of fluorescent signals simultaneously. The integrative use of cell-sorting, 16S rDNA sequencing, and fluorescence in situ hybridization (FISH) staining of the two-colored bacteria unveiled the taxonomic information of the donor endospores that germinated in the recipient's gut. Using this strategy, we investigated effects of different germinants and pre-treatment interventions on their germination, and found that germination of different commensal bacterial genera was distinctly affected by various types of germinants. This two-color labeling strategy shows its potential as a versatile tool for visually monitoring endospore germination in the hosts and screening for new interventions to improve endospore-based therapeutics.
Microcin MccI47 selectively inhibits enteric bacteria and reduces carbapenem-resistant <i>Klebsiella pneumoniae</i> colonization <i>in vivo</i> when administered <i>via</i> an engineered live biotherapeutic
Authors: Benedikt M. Mortzfeld, Jacob D. Palmer, Shakti K. Bhattarai, Haley L. Dupre, Regino Mercado-Lubio, Mark W. Silby, Corinna Bang, Beth A. McCormick, Vanni Bucci
Journal: Gut Microbes (2022)

The gastrointestinal (GI) tract is the reservoir for multidrug resistant (MDR) pathogens, specifically carbapenem-resistant (CR) Klebsiella pneumoniae and other Enterobacteriaceae, which often lead to the spread of antimicrobial resistance genes, severe extraintestinal infections, and lethal outcomes. Selective GI decolonization has been proposed as a new strategy for preventing transmission to other body sites and minimizing spreading to susceptible individuals. Here, we purify the to-date uncharacterized class IIb microcin I47 (MccI47) and demonstrate potent inhibition of numerous Enterobacteriaceae, including multidrug-resistant clinical isolates, in vitro at concentrations resembling those of commonly prescribed antibiotics. We then genetically modify the probiotic bacterium Escherichia coli Nissle 1917 (EcN) to produce MccI47 from a stable multicopy plasmid by using MccI47 toxin production in a counterselection mechanism to engineer one of the native EcN plasmids, which renders provisions for inducible expression and plasmid selection unnecessary. We then test the clinical relevance of the MccI47-producing engineered EcN in a murine CR K. pneumoniae colonization model and demonstrate significant MccI47-dependent reduction of CR K. pneumoniae abundance after seven days of daily oral live biotherapeutic administration without disruption of the resident microbiota. This study provides the first demonstration of MccI47 as a potent antimicrobial against certain Enterobacteriaceae, and its ability to significantly reduce the abundance of CR K. pneumoniae in a preclinical animal model, when delivered from an engineered live biotherapeutic product. This study serves as the foundational step toward the use of engineered live biotherapeutic products aimed at the selective removal of MDR pathogens from the GI tract.
Unilateral Endobronchial Vascular Hypertrophy in a Young Patient with Hemoptysis
Authors: Jacopo Saccomanno, Eva Pappe, Miriam Dulce, Elena Madlung, Frieder Gabriel, Jan-Moritz Doehn, Dirk Schürmann, Martin Witzenrath, Ralf-Harto Hübner
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

"Unilateral Endobronchial Vascular Hypertrophy in a Young Patient with Hemoptysis." American Journal of Respiratory and Critical Care Medicine, 207(2), pp. e1–e3
Traumatic brain injury: progress and challenges in prevention, clinical care, and research
Authors: Andrew I R Maas, David K Menon, Geoffrey T Manley, Mathew Abrams, Cecilia Åkerlund, Nada Andelic, Marcel Aries, Tom Bashford, Michael J Bell, Yelena G Bodien, Benjamin L Brett, András Büki, Randall M Chesnut, Giuseppe Citerio, David Clark, Betony Clasby, D Jamie Cooper, Endre Czeiter, Marek Czosnyka, Kristen Dams-O'Connor, Véronique De Keyser, Ramon Diaz-Arrastia, Ari Ercole, Thomas A van Essen, Éanna Falvey, Adam R Ferguson, Anthony Figaji, Melinda Fitzgerald, Brandon Foreman, Dashiell Gantner, Guoyi Gao, Joseph Giacino, Benjamin Gravesteijn, Fabian Guiza, Deepak Gupta, Mark Gurnell, Juanita A Haagsma, Flora M Hammond, Gregory Hawryluk, Peter Hutchinson, Mathieu van der Jagt, Sonia Jain, Swati Jain, Ji-yao Jiang, Hope Kent, Angelos Kolias, Erwin J O Kompanje, Fiona Lecky, Hester F Lingsma, Marc Maegele, Marek Majdan, Amy Markowitz, Michael McCrea, Geert Meyfroidt, Ana Mikolić, Stefania Mondello, Pratik Mukherjee, David Nelson, Lindsay D Nelson, Virginia Newcombe, David Okonkwo, Matej Orešič, Wilco Peul, Dana Pisică, Suzanne Polinder, Jennie Ponsford, Louis Puybasset, Rahul Raj, Chiara Robba, Cecilie Røe, Jonathan Rosand, Peter Schueler, David J Sharp, Peter Smielewski, Murray B Stein, Nicole von Steinbüchel, William Stewart, Ewout W Steyerberg, Nino Stocchetti, Nancy Temkin, Olli Tenovuo, Alice Theadom, Ilias Thomas, Abel Torres Espin, Alexis F Turgeon, Andreas Unterberg, Dominique Van Praag, Ernest van Veen, Jan Verheyden, Thijs Vande Vyvere, Kevin K W Wang, Eveline J A Wiegers, W Huw Williams, Lindsay Wilson, Stephen R Wisniewski, Alexander Younsi, John K Yue, Esther L Yuh, Frederick A Zeiler, Marina Zeldovich, Roger Zemek
Journal: The Lancet Neurology (2022)